The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NRBO | -63.28% | -99.94% | -76.93% | -100% |
| S&P | +12.83% | +86.37% | +13.24% | +111% |
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
No news articles found for MetaVia.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$5.00K | 0.0% |
| Market Cap | $22.77M | -16.6% |
| Market Cap / Employee | $2.53M | 0.0% |
| Employees | 9 | 12.5% |
| Net Income | -$3,377.00K | 40.3% |
| EBITDA | -$3,470.00K | 44.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.28M | -34.1% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00K | -100.0% |
| Short Term Debt | $79.00K | 5.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -87.87% | 26.3% |
| Return On Invested Capital | -199.23% | -34.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2,955.00K | 47.1% |
| Operating Free Cash Flow | -$2,955.00K | 47.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.21 | 3.04 | 1.62 | 3.60 | 70.68% |
| Price to Tangible Book Value | 14.84 | 18.45 | 13.98 | 26.00 | 71.80% |
| Enterprise Value to EBITDA | -0.30 | -1.22 | 1.78 | -2.52 | 45.29% |
| Return on Equity | -224.2% | -339.6% | -129.5% | -168.2% | 4.62% |
| Total Debt | $136.00K | $118.00K | $98.00K | $79.00K | -48.70% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
